Ask a health system CEO about their women's health strategy and you will hear two things. Labor and delivery. Mammography. Then they wipe their hands, and the checkbox is checked.

Priya Bathija spent nine years at the American Hospital Association building maternal and child health policy at national scale. In 2022 she left to found Nyoo Health, where she now advises hospitals and health systems on women's health strategy: what to build, what it returns, and which of the 400 point solutions sitting in the inbox are actually worth a pilot.

Her argument in this episode is not a moral one. It is a P&L one.

Procedures performed on female anatomy are reimbursed up to 30 to 40 percent less than comparable procedures on male anatomy, and that gap quietly drives service line decisions whether anyone says it out loud or not. McKinsey has put a number on what health systems leave on the table by not screening women adequately, and the number is billions. Women are 51 percent of the population, use roughly 10 percent more healthcare than men, and make the care decisions for their children, their spouses, and their parents. They are the most important customer in healthcare. Most systems are not treating them like a customer at all.

Then there is the part that lands hardest for anyone who owns a dashboard. Priya asks audiences how many of them stratify outcomes data by sex. Most do not. The ones who raise a hand are doing it for maternity care, which does not apply to men. One healthcare leader told her they could not stratify by sex because they do not collect that data. What Priya said back is the clip to send to your analytics lead.

Dr. Sarah Matt brings the bedside read: what happens when a research patient asks you to interpret her own scan, why digital literacy is not evenly distributed across a panel, and why treating all women as one population is the same error the field just spent a decade unlearning about everyone else.

What you will take away:

- Why a women's health strategy that stops at L&D and mammography is a revenue decision, not a care decision

- The reimbursement gap between female and male anatomy procedures, and how it shapes what gets built

- The business case for midlife and menopause programs, and the referral economics that follow

- What happens to your record when a patient gets hormones or a GLP-1 from a virtual provider you are not connected to

- Why almost nobody stratifies outcomes by sex, and the cop-out leaders use to avoid it

- Where consumer-facing AI actually helps patients (appointment prep, reading their own results, disputing a bill) and who should pay for it

- How to pick the one women's health investment your community needs instead of the one with the best shine

Find Priya: LinkedIn https://www.linkedin.com/in/pbathija | Nyoo Health https://www.nyoohealth.com | The Women's Health Playbook, wherever you listen

Mentioned in this episode: Meghan Rabbitt, "The New Rules of Women's Health"

—

Resources & Links:

📖 Get the Book: "The Borderless Healthcare Revolution" is available now on Amazon and major retailers.

💼 Work with Dr. Matt:
Looking for a keynote speaker or strategic advisor?
Visit: drsarahmatt.com

🔗 Connect on Social:
LinkedIn: https://www.linkedin.com/in/sarahmattmd/
YouTube: https://www.youtube.com/@DrSarahMatt-ClinicalRealist

📧 Subscribe to The Briefing: drsarahmatt.com/newsletter-signup
 
—
Disclaimer:
The views expressed on this podcast are those of Dr. Sarah Matt and her guests. They do not necessarily reflect the official policy or position of any affiliated institutions. This content is for informational and educational purposes only and does not constitute medical advice or a professional consulting relationship.

Most clinical trial eligibility criteria are written by people who have never run a site.

Lisa Sonneborn has run one for 15 years. She built the first stand-alone clinical trial facility in Upstate New York, focused on Alzheimer's and NASH research. Watched sponsor after sponsor send protocols with visit schedules, lab windows, and exclusion lists that were scientifically defensible and operationally unworkable. She would look at the eligibility section and know within the first three line items whether the trial was designed for the patients or for the data.

In 2024, she co-founded Ichor Research in Syracuse: diagnostic trials for cancer, neurodegeneration, metabolic conditions, substance abuse. The markets large CROs do not prioritize. The patients clinical research has historically passed over.

In this episode of The Clinical Realist, Dr. Sarah Matt and Lisa Sonneborn cover the specific protocol features that flag a trial was designed without a real site in mind, what the visit-burden dropout math actually looks like at a small independent site, how AI lands in practice at a three-person team in Upstate New York, the case for running diagnostic research in Syracuse, and what a different five-year future for clinical trial access looks like if small independent sites actually win.

What you will take away:

- The eligibility list red flag that signals a protocol was not designed for real patients

- What dropout math looks like at a small site versus what the protocol assumed

- How AI is actually used at Ichor Research versus the pitch version

- Why small independent sites reach patients that large CROs skip

- What Lisa built differently the second time, knowing what she learned from selling the first business

Find Lisa: LinkedIn https://www.linkedin.com/in/lisa-sonneborn-ma-lmhc-17047a63/ | Ichor Research https://ichorlifesciences.com

Book a Discovery and Clarity Session: https://calendly.com/sarahmattmd

Subscribe to The Sarah Matt Briefing: https://drsarahmatt.com/newsletter-signup

—

Resources & Links:

📖 Get the Book: "The Borderless Healthcare Revolution" is available now on Amazon and major retailers.

💼 Work with Dr. Matt:
Looking for a keynote speaker or strategic advisor?
Visit: drsarahmatt.com

🔗 Connect on Social:
LinkedIn: https://www.linkedin.com/in/sarahmattmd/
YouTube: https://www.youtube.com/@DrSarahMatt-ClinicalRealist

📧 Subscribe to The Briefing: drsarahmatt.com/newsletter-signup
 
—
Disclaimer:
The views expressed on this podcast are those of Dr. Sarah Matt and her guests. They do not necessarily reflect the official policy or position of any affiliated institutions. This content is for informational and educational purposes only and does not constitute medical advice or a professional consulting relationship.

People whose care is scattered across multiple providers, with no single person or system holding the whole picture, have more than double the risk of dying, even after accounting for how sick they already are. Amy Andrade has spent her career on that gap.

In this episode of The Clinical Realist, Dr. Sarah Matt talks with Amy Andrade, Co-Founder and Chief Product Officer of Alphiniti and a biomedical data science researcher at Meharry Medical College. Alphiniti is building person-centric data continuity, infrastructure that keeps one person's record connected across health, financial, and legacy systems instead of scattered across every institution they have ever touched. Amy is also an active advisory client, so this conversation flips the mic on a build Sarah has watched from the inside.

The conversation covers what continuity looks like as a shipped product rather than a slide in a deck, the split between institutional (B2B) and consumer-facing (B2B2C) buyers, why AI tools built to fix fragmentation can fail silently for the people already falling through the cracks, the middleware critique and where it does and does not hold up, and how a company Alphiniti's size competes for this category before Big Tech, already signaling interest in the same space, claims it.

What you will take away:

- Why fragmented data carries a measurable mortality cost, not just an inconvenience

- What continuity actually means as a product, not a pitch-deck slide

- How B2B and B2B2C buyers value the same infrastructure differently

- Where the data-continuity-as-middleman critique is fair, and where it isn't

- What has to be true for a company like Alphiniti to win this category

Find Amy and Alphiniti: alphiniti.com

Book a Discovery and Clarity Session: https://calendly.com/sarahmattmd

Subscribe to The Sarah Matt Briefing: https://drsarahmatt.com/newsletter-signup

—

Resources & Links:

📖 Get the Book: "The Borderless Healthcare Revolution" is available now on Amazon and major retailers.

💼 Work with Dr. Matt:
Looking for a keynote speaker or strategic advisor?
Visit: drsarahmatt.com

🔗 Connect on Social:
LinkedIn: https://www.linkedin.com/in/sarahmattmd/
YouTube: https://www.youtube.com/@DrSarahMatt-ClinicalRealist

📧 Subscribe to The Briefing: drsarahmatt.com/newsletter-signup
 
—
Disclaimer:
The views expressed on this podcast are those of Dr. Sarah Matt and her guests. They do not necessarily reflect the official policy or position of any affiliated institutions. This content is for informational and educational purposes only and does not constitute medical advice or a professional consulting relationship.

Most healthtech founders solve a real clinical problem, get piloted in a few systems, and then discover that solving the clinical problem was never the same thing as building a company someone would actually buy. Dr. Roxie Mooney, DBA, has spent her career on that exact gap.

In this episode of The Clinical Realist, Dr. Sarah Matt talks with Dr. Roxie Mooney, founder and CEO of Legacy DNA, where she works with midmarket healthtech and pharmacy companies, often private-equity backed, who are twelve to thirty-six months out from an acquisition or a capital event. She holds a Doctorate in Business Administration focused on commercializing healthcare technology. She helped scale BioPlus Specialty Pharmacy from roughly 750 million dollars to 2 billion in revenue, which led to back-to-back acquisitions by Nautic Partners and then Elevance Health, and she has been part of four successful exits.

The conversation covers what an acquirer is actually buying, why most healthtech companies are commercially unready long before they think they are, pilotitis from the commercialization side, the first metric a strategic acquirer opens the diligence folder to find, where pharma and healthtech commercial logic split, and what the current deal climate means for a company eighteen months from an exit.

What you will take away:

- What a strategic acquirer is actually buying, beyond the clinical science

- The signs a founder does not yet understand what makes a company acquirable

- Why pilotitis is the enemy of exit readiness

- The first metric in the diligence folder

- A clear read on the current M and A climate for healthtech

Find Roxie: LinkedIn https://www.linkedin.com/in/roxiemooney/ | Substack https://healthinnovatorsedge.substack.com | Book: How Health Innovators Maximize Market Success | Company: Legacy DNA (https://legacy-dna.com)

Book a Discovery and Clarity Session: https://calendly.com/sarahmattmd

Subscribe to The Sarah Matt Briefing: https://drsarahmatt.com/newsletter-signup

—

Resources & Links:

📖 Get the Book: "The Borderless Healthcare Revolution" is available now on Amazon and major retailers.

💼 Work with Dr. Matt:
Looking for a keynote speaker or strategic advisor?
Visit: drsarahmatt.com

🔗 Connect on Social:
LinkedIn: https://www.linkedin.com/in/sarahmattmd/
YouTube: https://www.youtube.com/@DrSarahMatt-ClinicalRealist

📧 Subscribe to The Briefing: drsarahmatt.com/newsletter-signup
 
—
Disclaimer:
The views expressed on this podcast are those of Dr. Sarah Matt and her guests. They do not necessarily reflect the official policy or position of any affiliated institutions. This content is for informational and educational purposes only and does not constitute medical advice or a professional consulting relationship.

Two years ago, every health system was running an AI pilot. Today, most are still running AI pilots. The technology improved dramatically. The deployment gap between what a board approves and what happens in an exam room stayed the same.

In this episode of The Clinical Realist, Dr. Sarah Matt talks with Dr. Robert Pearl about what that gap looks like from inside a system that actually closed it. Pearl was CEO of The Permanente Medical Group and Co-CEO of Kaiser Permanente for 18 years, running 22,000 physicians and 103,000 staff while practicing facial plastic surgery. He is now a clinical professor at Stanford GSB and the School of Medicine, and the author of ChatGPT, MD: How AI-Empowered Patients and Doctors Can Take Back Control of American Medicine.

The conversation covers the part that does not fit on a conference slide: the honest before-and-after between narrow AI and generative AI, why patients gaining information parity with physicians is a power shift and not just a convenience, the diagnostic error comparison that almost no one in medicine will make publicly, and what it actually takes to close the boardroom-to-care-floor seam before the tools scale past the governance.

What you will take away:

- The honest clinical difference between the first wave of narrow AI and generative AI in practice (not in press releases)

- Why physician resistance to AI second-opinions is about power structure, not just liability or hallucinations

- The diagnostic error comparison between AI and physicians, and why the data is not being discussed publicly

- What health system boards are being told about AI ROI versus what is actually happening in exam rooms

- Where the governance needs to be before the tools scale

Book a Discovery and Clarity Session: https://calendly.com/sarahmattmd

Subscribe to The Sarah Matt Briefing: https://drsarahmatt.com/newsletter-signup

—

Resources & Links:

📖 Get the Book: "The Borderless Healthcare Revolution" is available now on Amazon and major retailers.

💼 Work with Dr. Matt:
Looking for a keynote speaker or strategic advisor?
Visit: drsarahmatt.com

🔗 Connect on Social:
LinkedIn: https://www.linkedin.com/in/sarahmattmd/
YouTube: https://www.youtube.com/@DrSarahMatt-ClinicalRealist

📧 Subscribe to The Briefing: drsarahmatt.com/newsletter-signup
 
—
Disclaimer:
The views expressed on this podcast are those of Dr. Sarah Matt and her guests. They do not necessarily reflect the official policy or position of any affiliated institutions. This content is for informational and educational purposes only and does not constitute medical advice or a professional consulting relationship.

Patient experience gets treated as a soft metric. Amanda Brummitt, FACHE, has spent 25+ years in health system operations proving it is a margin lever, a retention lever, and the first thing most AI rollouts ignore.\n\nIn this episode of The Clinical Realist, Dr. Sarah Matt sits down with Amanda Brummitt, Principal of Brummitt Group, to unpack why patient experience is strategy, not sentiment, and what health system leaders get wrong when they bolt AI onto a broken experience.\n\nGuest: Amanda Brummitt, FACHE, Principal, Brummitt Group\nHost: Dr. Sarah Matt, MD, MBA, surgery-trained physician-executive\n\ndrsarahmatt.com | https://calendly.com/sarahmattmd

—

Resources & Links:

📖 Get the Book: "The Borderless Healthcare Revolution" is available now on Amazon and major retailers.

💼 Work with Dr. Matt:
Looking for a keynote speaker or strategic advisor?
Visit: drsarahmatt.com

🔗 Connect on Social:
LinkedIn: https://www.linkedin.com/in/sarahmattmd/
YouTube: https://www.youtube.com/@DrSarahMatt-ClinicalRealist

📧 Subscribe to The Briefing: drsarahmatt.com/newsletter-signup
 
—
Disclaimer:
The views expressed on this podcast are those of Dr. Sarah Matt and her guests. They do not necessarily reflect the official policy or position of any affiliated institutions. This content is for informational and educational purposes only and does not constitute medical advice or a professional consulting relationship.

Dr. Marschall Runge, MD, PhD, Dean of the University of Michigan Medical School and CEO of Michigan Medicine, sits across the table from health tech founders every day. In this episode, he shares the institutional reality that most health tech companies never see: what it actually takes for an academic medical center to say yes. Not the demo. Not the pilot. The governance questions, the budget structures, the clinical workflow realities, and the leadership calculus that decides whether a tool survives past the first quarter. If you build for health systems, or you are trying to scale inside one, this is the conversation that explains why the buyer behaves the way they do.

—

Resources & Links:

📖 Get the Book: "The Borderless Healthcare Revolution" is available now on Amazon and major retailers.

💼 Work with Dr. Matt:
Looking for a keynote speaker or strategic advisor?
Visit: drsarahmatt.com

🔗 Connect on Social:
LinkedIn: https://www.linkedin.com/in/sarahmattmd/
YouTube: https://www.youtube.com/@DrSarahMatt-ClinicalRealist

📧 Subscribe to The Briefing: drsarahmatt.com/newsletter-signup
 
—
Disclaimer:
The views expressed on this podcast are those of Dr. Sarah Matt and her guests. They do not necessarily reflect the official policy or position of any affiliated institutions. This content is for informational and educational purposes only and does not constitute medical advice or a professional consulting relationship.

The AI tool you bought last quarter, the one bundled into your EHR upgrade, the one your hospital piloted on your unit. Was it cleared by the FDA as a medical device? Most physicians do not know the answer. In this episode of The Clinical Realist, Dr. Sarah Matt walks listeners through three questions: when is an AI tool a medical device, what do the three FDA approval pathways (510(k), De Novo, PMA) actually mean about the evidence behind a product, and what does professional liability look like when the algorithm is the one making the call. Book a Discovery and Clarity Session: calendly.com/sarahmattmd

—

Resources & Links:

📖 Get the Book: "The Borderless Healthcare Revolution" is available now on Amazon and major retailers.

💼 Work with Dr. Matt:
Looking for a keynote speaker or strategic advisor?
Visit: drsarahmatt.com

🔗 Connect on Social:
LinkedIn: https://www.linkedin.com/in/sarahmattmd/
YouTube: https://www.youtube.com/@DrSarahMatt-ClinicalRealist

📧 Subscribe to The Briefing: drsarahmatt.com/newsletter-signup
 
—
Disclaimer:
The views expressed on this podcast are those of Dr. Sarah Matt and her guests. They do not necessarily reflect the official policy or position of any affiliated institutions. This content is for informational and educational purposes only and does not constitute medical advice or a professional consulting relationship.

The AI tool you bought last quarter, the one bundled into your EHR upgrade, the one your hospital piloted on your unit. Was it cleared by the FDA as a medical device? Most physicians do not know the answer. The vendor's pitch deck almost certainly did not lead with it. And the answer matters, because once an algorithm crosses into FDA medical device territory, the rules that govern what it can claim, how it has to perform, who is liable when it fails, and what evidence the manufacturer had to produce before it reached your practice change categorically.

In this episode of The Clinical Realist, Dr. Sarah Matt walks listeners through three questions: when is an AI tool a medical device, what do the three FDA approval pathways actually mean about the evidence behind a product, and what does professional liability look like when the algorithm is the one making the call.

What you will take away:

- When a clinical AI tool crosses the line into FDA-regulated medical device territory

- What 510(k), De Novo, and PMA clearance pathways actually say about the evidence behind a product

- Why the word cleared is doing enormous amounts of work in this industry

- What changes for physicians, procurement teams, and health system leaders when the algorithm is making the call

Book a Discovery and Clarity Session: https://calendly.com/sarahmattmd

Subscribe to The Sarah Matt Briefing: https://drsarahmatt.com/newsletter-signup

—

Resources & Links:

📖 Get the Book: "The Borderless Healthcare Revolution" is available now on Amazon and major retailers.

💼 Work with Dr. Matt:
Looking for a keynote speaker or strategic advisor?
Visit: drsarahmatt.com

🔗 Connect on Social:
LinkedIn: https://www.linkedin.com/in/sarahmattmd/
YouTube: https://www.youtube.com/@DrSarahMatt-ClinicalRealist

📧 Subscribe to The Briefing: drsarahmatt.com/newsletter-signup
 
—
Disclaimer:
The views expressed on this podcast are those of Dr. Sarah Matt and her guests. They do not necessarily reflect the official policy or position of any affiliated institutions. This content is for informational and educational purposes only and does not constitute medical advice or a professional consulting relationship.

Medical school teaches you pathophysiology, pharmacology, and clinical reasoning. It does not teach you how the money actually works.

In this episode, Dr. Sarah Matt breaks down the economic structures that govern every clinical decision, every technology purchase, and every AI pilot that dies in a committee room: who pays, who decides, who uses, and why those three people are almost never the same person.

What you will take away:

- The user / decider / payer split and why it explains nearly every failed health-tech deal

- How the RVU system shapes physician behavior and silently resists AI adoption

- Why value-based care is harder to execute than the architects planned for

- The practical questions buyers, vendors, and physicians should be asking before any AI deployment

If you want to understand why healthcare moves so slowly, start here.

Book a Discovery and Clarity Session: https://calendly.com/sarahmattmd

Subscribe to The Sarah Matt Briefing: https://drsarahmatt.com/newsletter-signup

—

Resources & Links:

📖 Get the Book: "The Borderless Healthcare Revolution" is available now on Amazon and major retailers.

💼 Work with Dr. Matt:
Looking for a keynote speaker or strategic advisor?
Visit: drsarahmatt.com

🔗 Connect on Social:
LinkedIn: https://www.linkedin.com/in/sarahmattmd/
YouTube: https://www.youtube.com/@DrSarahMatt-ClinicalRealist

📧 Subscribe to The Briefing: drsarahmatt.com/newsletter-signup
 
—
Disclaimer:
The views expressed on this podcast are those of Dr. Sarah Matt and her guests. They do not necessarily reflect the official policy or position of any affiliated institutions. This content is for informational and educational purposes only and does not constitute medical advice or a professional consulting relationship.